About
David Hirsch is a founder and Managing Director of Longitude Capital. He focuses on investments in biotechnology. From 2005 to 2006, David Hirsch was a Vice President of Pequot Ventures where he worked in the life sciences practice. Prior to Pequot, David Hirsch was an Engagement Manager in the pharmaceutical practice of McKinsey & Company. While at McKinsey, he worked with many large pharmaceutical companies across a range of projects including clinical and commercial strategies, M&A evaluations, portfolio prioritization and managed care strategy. He currently serves on the boards of Civitas Therapeutics and Precision Therapeutics and is a board observer at InfaCare Pharmaceuticals and Xanodyne Pharmaceuticals. He is also actively involved with Longitude’s investments in Amarin (NASDAQ: AMRN) and Corcept Therapeutics (NASDAQ: CORT), as well as prior investments in Horizon Therapeutics and Sequenom (NASDAQ: SQNM).
Position in the VCSift Database
- • 13 investors at Longitude Capital are tracked.
- • 1,801 investors hold the Managing Director role in VCSift. David Hirsch is one of them.
- • 2,799 investors are based in United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- US
Contact Information
Find more investors like David
Search Investors